ArticleJournal of molecular modeling2026
Molecular modeling design of antitrypanosomal pyrazolone derivatives targeting Chagas disease: QSAR, docking, molecular dynamics and free energy calculations.
Article in Journal of molecular modeling, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
contextChagas disease, caused by T. cruzi, remains a neglected tropical disease with limited therapeutic options, underscoring the urgent need for novel antitrypanosomal agents. A computer-aided drug design (CADD) protocol was applied to investigate pyrazolone derivatives with reported antitrypanosomal activity and their putative interaction with cruzain (Cz), a cysteine protease essential for parasite survival. A 2D-QSAR model built from a curated set of 33 phenyl-dihydropyrazolone derivatives guided the design of four new candidates (LMM1-LMM4), which showed intermediate predicted antitrypanosomal activity within the chemical space of the original pyrazolone series. Molecular docking identified favorable binding within the Cz active site, with contacts at residues Ser61, Gly66, and Leu67. MD simulations indicated overall structural stability of the protein-ligand complexes and revealed ligand-dependent conformational behavior within the Cz binding site. MM/GBSA calculations suggested that van der Waals interactions are major contributors to the computed binding energies; however, the MM/GBSA ranking did not fully reproduce the phenotypic antitrypanosomal activity trend. Per-residue decomposition and free energy landscape analyses were therefore interpreted qualitatively, suggesting that contacts with S2/S3 subsite residues and conformational adaptability may contribute to Cz recognition but do not, alone, explain whole-cell potency. These findings support pyrazolones as antitrypanosomal scaffolds and provide structural hypotheses for future experimental validation against Cz.
methodsMolecular geometries were optimized at the PM6 level (MOPAC2016); descriptors were calculated with ChemDes and UseGalaxy, selected via OPS and a genetic algorithm (QSARINS), and the QSAR model was built using PLS regression (QSAR modeling software). Molecular docking was performed with GOLD, FITTED, and AutoDock Vina 1.2.3 against Cz (PDB: 3KKU). ADMET properties were predicted using OSIRIS Property Explorer, SwissADME, and ADMET-AI. Partial atomic charges were derived at the HF/6-31G* level with RESP fitting (Gaussian 09); MD simulations (3 × 250 ns per system) were run with AMBER20 using GAFF/ff14SB force fields and TIP3P solvent. Binding free energies were calculated by MM/GBSA (MMPBSA.py).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.